Concepedia

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence, Catherine Delbaldo, Karina Vera, Véronique Girre, Judy H. Chiao, Sian Armour, Sheelagh Frame, Simon R. Green,

European Journal of Cancer · 2010 · 167 citations · 21 references

DOI

Concepts

References

21

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Role of the INK4a Locus in Tumor Suppression and Cell Mortality

Manuel Serrano, Han‐Woong Lee, Lynda Chin et al. · Cell · 1996 · 1.6K citations · Full text

, , +16

<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Steven J. McClue, David Blake, Rosemary G. Clarke et al. · International Journal of Cancer · 2002 · 363 citations · Full text

, , +15

Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

Gero Kramer, Hamdiye Erdal, H Mertens et al. · Cancer Research · 2004 · 283 citations

, , +15

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Charlotte Benson, Jeff White, Johann S. de Bono et al. · British Journal of Cancer · 2006 · 259 citations · Full text

, , +14